Skip to content

Peripheral blood ctDNA MTDH detection for endocrine therapy prognosis of breast cancer.

Multivariate evaluation of the peripheral blood ctDNA MTDH and breast cancer endocrine therapy efficacy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17012109
Enrollment
Unknown
Registered
2017-07-24
Start date
2017-08-01
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Gold Standard:Breast cancer local recurrence or distant metastasis of the reference standard: physical examination, breast ultrasound, head?chest and abdomen enhanced CT, head MRI, bone ECT scan, tumo
blood&#32
MTDH

Sponsors

Affiliated Nanhua hospital, University of South China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged 18-80 years old; estrogen receptor-positive breast cancer patients; Pathology I to III stagy; tolerant tamoxifen long-term treatment; agreed to participate in clinical trials; to complete the extraction of peripheral blood and successful detection of ctDNA MTDH.

Exclusion criteria

Exclusion criteria: Clinical advanced breast cancer; estrogen receptor-negative breast cancer patients; do not accept or can not tolerate tamoxifen long-term treatment; do not agree to participate in clinical trials; can not complete the peripheral blood extraction or can not detect ctDNA MTDH.

Design outcomes

Secondary

MeasureTime frame
physical examination;breast ultrasound;head?chest and abdomen enhanced CT;bone ECT scan;tumor standard test: CA125, CA153, CEA;

Primary

MeasureTime frame
peripheral blood ctDNA MTDH;tissue pathology;

Countries

China

Contacts

Public ContactSong Wang

Affiliated Nanhua hospital, University of South China

108431968@qq.com+86 13875796386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026